Elisabet E. Manasanch, MD

Articles

Final Thoughts on Case Study and Treating Multiple Myeloma

January 12th 2023

Dr Joseph Mikhael and expert panel re-visit the patient case and offer their final thoughts on the impact of clinical trial updates in the treatment landscape of multiple myeloma.

Clinical Trials in R/R Multiple Myeloma

January 12th 2023

Dr Joseph Mikhael and expert panel discuss key efficacy and safety outcomes of pivotal clinical trials evaluating treatment regimens in patients with R/R multiple myeloma.

Treatment Options in Early Relapse Multiple Myeloma

January 5th 2023

Dr Joseph Mikhael and expert panel review current treatment options for patients with early relapse multiple myeloma, in accordance with current NCCN guidelines.

Case Study: Myeloma at Early Relapse

January 5th 2023

Dr Joseph Mikhael and expert panel review a case study in early relapse multiple myeloma and the impact of cytogenetics in risk assessment for patients with early relapse multiple myeloma.

Frontline Therapy in Multiple Myeloma

December 22nd 2022

Joseph Mikhael, MD, discusses diagnosis criteria and treatment considerations for patients with multiple myeloma in the frontline setting.

Dr. Manasanch on Eligibility for Autologous Transplant in Multiple Myeloma

September 28th 2021

Elisabet E. Manasanch, MD, discusses eligibility for autologous stem cell transplant in patients with multiple myeloma.

Dr. Manasanch on Key Takeaways From CASSIOPEIA in Multiple Myeloma

August 3rd 2021

Elisabet E. Manasanch, MD, discusses key lessons learned from the phase 3 CASSIOPEIA trial in patients with newly diagnosed multiple myeloma.

Dr. Manasanch on Outcomes With Elranatamab in Multiple Myeloma

August 2nd 2021

Elisabet E. Manasanch, MD, discusses outcomes seen with elranatamab in patients with relapsed or refractory multiple myeloma.